PR Newswire Clinical TrialsOriginal article
StimCardio's NeuroPulse Study Reports Substantial Reduction in Recurrent Atrial Fibrillation Events Via Non-Invasive Wearable Neuromodulation Following Ablation
Data ReadoutpositiveNeuroPulsePositive
AI Analysis
Summary
StimCardio's NeuroPulse non-invasive wearable neuromodulation device demonstrated 90% freedom from atrial arrhythmias at six months versus 80.8% with sham in a randomized, double-blind, sham-controlled trial. Results were presented as late-breaking clinical science at HRX Live 2026 and published in Heart Rhythm journal.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
90% freedom from atrial arrhythmias at six months with neuromodulation vs. 80.8% with sham in randomized, double-blind, sham-controlled trial
Importance:7/10
Sentiment:
0.85
atrial fibrillationneuromodulationwearable deviceclinical triallate-breaking datasham-controlled
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 20, 2026 3:00 PM